Carmen Loquai

26.2k total citations · 2 hit papers
141 papers, 4.6k citations indexed

About

Carmen Loquai is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Carmen Loquai has authored 141 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 83 papers in Molecular Biology and 28 papers in Immunology. Recurrent topics in Carmen Loquai's work include Melanoma and MAPK Pathways (61 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Cutaneous Melanoma Detection and Management (35 papers). Carmen Loquai is often cited by papers focused on Melanoma and MAPK Pathways (61 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Cutaneous Melanoma Detection and Management (35 papers). Carmen Loquai collaborates with scholars based in Germany, United States and France. Carmen Loquai's co-authors include Ralf Gutzmer, Reinhard Dummer, Dirk Schadendorf, Claus Garbe, Caroline Robert, Stephan Grabbe, Lisa Zimmer, Ana Arance, Paolo A. Ascierto and Ivana Krajsová and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Carmen Loquai

138 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carmen Loquai Germany	30	3.1k	2.1k	956	597	499	141	4.6k
Lisa Zimmer Germany	33	3.1k 1.0×	1.5k 0.7×	987 1.0×	452 0.8×	644 1.3×	155	4.3k
Pippa Corrie United Kingdom	35	3.0k 1.0×	1.5k 0.7×	802 0.8×	638 1.1×	731 1.5×	176	4.8k
Karl D. Lewis United States	41	4.9k 1.6×	4.0k 1.9×	1.5k 1.6×	1.5k 2.4×	813 1.6×	177	7.8k
Jacob Schachter Israel	47	6.5k 2.1×	3.0k 1.4×	3.0k 3.1×	690 1.2×	857 1.7×	189	8.4k
Lawrence E. Flaherty United States	38	3.5k 1.1×	2.4k 1.1×	1.7k 1.8×	315 0.5×	1.2k 2.4×	117	5.4k
Laurent Mortier France	43	4.7k 1.5×	3.4k 1.6×	1.7k 1.7×	1.5k 2.5×	1.4k 2.8×	307	8.1k
René González United States	48	6.6k 2.1×	4.4k 2.1×	2.6k 2.8×	723 1.2×	1.2k 2.3×	189	9.2k
Bastian Schilling Germany	36	2.8k 0.9×	1.3k 0.6×	2.1k 2.2×	388 0.6×	493 1.0×	131	4.7k
Antonio Cossu Italy	34	1.8k 0.6×	1.9k 0.9×	380 0.4×	352 0.6×	586 1.2×	195	4.0k
Semir Vranić Qatar	36	2.6k 0.8×	1.6k 0.8×	476 0.5×	569 1.0×	966 1.9×	228	5.1k

Countries citing papers authored by Carmen Loquai

Since Specialization

Citations

This map shows the geographic impact of Carmen Loquai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Loquai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Loquai more than expected).

Fields of papers citing papers by Carmen Loquai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Loquai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Loquai. The network helps show where Carmen Loquai may publish in the future.

Co-authorship network of co-authors of Carmen Loquai

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Loquai. A scholar is included among the top collaborators of Carmen Loquai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Loquai. Carmen Loquai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations

Ascierto, Paolo A., Reinhard Dummer, Helen Gogas, et al.. (2023). Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology. 41(29). 4621–4631. 15 indexed citations

Salzmann, Martin, Alexander Wald, Henner Stege, et al.. (2023). Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study. Cancers. 15(5). 1426–1426. 1 indexed citations

Schadendorf, Dirk, Reinhard Dummer, K. T. Flaherty, et al.. (2023). 1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma. Annals of Oncology. 34. S670–S671. 3 indexed citations

Haydon, Andrew, Dirk Schadendorf, Reinhard Dummer, et al.. (2023). 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 34. S1707–S1708. 2 indexed citations

Salzmann, Martin, Carmen Loquai, David Rafei‐Shamsabadi, et al.. (2022). MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. European Journal of Cancer. 166. 24–32. 11 indexed citations

Hassel, J.C., Thomas Eigentler, Carmen Loquai, et al.. (2022). 784O Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial. Annals of Oncology. 33. S900–S900. 1 indexed citations

Haist, Maximilian, Henner Stege, Claudine Graf, et al.. (2021). Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study. Cancers. 13(20). 5103–5103. 34 indexed citations

Mitzel-Rink, Heidrun, et al.. (2021). Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. Cancer Medicine. 10(5). 1562–1575. 16 indexed citations

10.

Gutzmer, Ralf, et al.. (2021). Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer. 21(1). 1244–1244. 13 indexed citations

11.

Kähler, Katharina C., Jessica C. Hassel, Lucie Heinzerling, et al.. (2020). Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 18(6). 582–609. 21 indexed citations

12.

Lebbé, Célèste, Caroline Dutriaux, Thierry Lesimple, et al.. (2020). Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers. 12(7). 1727–1727. 32 indexed citations

13.

Dummer, Reinhard, Ralf Gutzmer, John T. Lear, et al.. (2019). Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study. British Journal of Dermatology. 182(6). 1369–1378. 123 indexed citations

14.

Augustin, Matthias, Christine Blome, Andrea Forschner, et al.. (2018). Willingness to pay for a cure of low-risk melanoma patients in Germany. PLoS ONE. 13(5). e0197780–e0197780. 9 indexed citations

15.

Zimmer, Lisa, Zeynep Eroglu, Lisa A. Kottschade, et al.. (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer. 75. 47–55. 128 indexed citations

16.

Hassel, Jessica C., Kristina Buder‐Bakhaya, Carolin Bender, et al.. (2017). Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine. 7(1). 95–104. 13 indexed citations

17.

Lear, John T., Michael R. Migden, Karl D. Lewis, et al.. (2017). Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venereology. 32(3). 372–381. 137 indexed citations

18.

Lear, John T., Ralf Gutzmer, Michael R. Migden, et al.. (2016). Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis. Melanoma Research. 1 indexed citations

19.

Barckhausen, Christina, Karl-Heinz Tomaszowski, Carmen Loquai, et al.. (2016). Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Cancer Research. 76(10). 3067–3077. 77 indexed citations

20.

Luger, TA, et al.. (2004). Imiquimod, pegyliertes Interferon-?-2b und Interleukin-2 in der Behandlung kutaner Melanommetastasen. Der Hautarzt. 55(2). 176–181. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact